Back to Search Start Over

Nuclear IL‐33/SMAD signaling axis promotes cancer development in chronic inflammation.

Authors :
Park, Jong Ho
Ameri, Amir H
Dempsey, Kaitlin E
Conrad, Danielle N
Kem, Marina
Mino‐Kenudson, Mari
Demehri, Shadmehr
Source :
EMBO Journal. Apr2021, Vol. 40 Issue 7, p1-16. 16p.
Publication Year :
2021

Abstract

Interleukin (IL)‐33 cytokine plays a critical role in allergic diseases and cancer. IL‐33 also has a nuclear localization signal. However, the nuclear function of IL‐33 and its impact on cancer is unknown. Here, we demonstrate that nuclear IL‐33‐mediated activation of SMAD signaling pathway in epithelial cells is essential for cancer development in chronic inflammation. Using RNA and ChIP sequencing, we found that nuclear IL‐33 repressed the expression of an inhibitory SMAD, Smad6, by interacting with its transcription factor, RUNX2. IL‐33 was highly expressed in the skin and pancreatic epithelial cells in chronic inflammation, leading to a markedly repressed Smad6 expression as well as dramatically upregulated p‐SMAD2/3 and p‐SMAD1/5 in the epithelial cells. Blocking TGF‐β/SMAD signaling attenuated the IL‐33‐induced cell proliferation in vitro and inhibited IL‐33‐dependent epidermal hyperplasia and skin cancer development in vivo. IL‐33 and SMAD signaling were upregulated in human skin cancer, pancreatitis, and pancreatitis‐associated pancreatic cancer. Collectively, our findings reveal that nuclear IL‐33/SMAD signaling is a cell‐autonomous tumor‐promoting axis in chronic inflammation, which can be targeted by small‐molecule inhibitors for cancer treatment and prevention. The cell‐autonomous functions of cytokines and their impact on cancer promotion are unclear. Here, we demonstrate that nuclear IL‐33 promotes epithelial carcinogenesis in chronic inflammation independent of its cytokine function. IL‐33 is highly induced and localized in the epithelial cell nuclei of the skin and pancreas affected by chronic inflammation.Nuclear IL‐33 upregulates SMAD signaling in epithelial cells by repressing the expression of Smad6 (an inhibitory SMAD).Nuclear IL‐33 binds to the RUNX2 transcription factor to block Smad6 expression.Nuclear IL‐33 promotes epithelial cell proliferation and tumor development by upregulating SMAD signaling in cancer‐prone chronic inflammation of skin and pancreas. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02614189
Volume :
40
Issue :
7
Database :
Academic Search Index
Journal :
EMBO Journal
Publication Type :
Academic Journal
Accession number :
149597953
Full Text :
https://doi.org/10.15252/embj.2020106151